Preliminary phase 2 results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate cancer patients

被引：0
|
作者：
Cook, Natalie
Bernard-Tessier, Alice
Barthelemy, Philippe
Utriainen, Tapio
Roubaud, Guilhem
Flechon, Aude
van der Voet, Hans
Gravis Mescam, Gwenaelle
Ratta, Raffaele
Jones, Rob
Parikh, Omi
Tanner, Minna
Garratt, Chris
Nevalaita, Liina
Pohjanjousi, Pasi
Ikonen, Tarja
Antonarakis, Emmanuel
Fizazi, Karim
机构：
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs57
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [41] A study of two ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC)
    Massard, Christophe
    Tammela, Teuvo L. J.
    Vjaters, Egils
    Lietuvietis, Vilnis
    Bono, Petri
    Penttinen, Heidi
    Nykanen, Pirjo
    Snapir, Amir
    Mattila, Leena
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [42] PHASE 2 TRIAL OF A DNA VACCINE WITH PEMBROLIZUMAB IN PATIENTS WITH METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    McNeel, Douglas
    Eickhoff, Jens
    Wargowski, Ellen
    Johnson, Laura
    Kyriakopoulos, Christos
    Emamekhoo, Hamid
    Lang, Joshua
    Brennan, Mary Jane
    Liu, Glenn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A377 - A377
  • [43] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [44] Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
    Rathkopf, Dana E.
    Larson, Steven M.
    Anand, Aseem
    Morris, Michael J.
    Slovin, Susan F.
    Shaffer, David R.
    Heller, Glenn
    Carver, Brett
    Rosen, Neal
    Scher, Howard I.
    CANCER, 2015, 121 (21) : 3853 - 3861
  • [45] Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results
    Chi, Kim N.
    Fleshner, Neil
    Chiuri, Vincenzo Emanuele
    Van Bruwaene, Siska
    Hafron, Jason
    McNeel, Douglas G.
    De Porre, Peter
    Maul, Raymond Scott
    Daksh, Mahesh
    Zhong, Xiaogang
    Mason, Gary E.
    Tutrone, Ronald F.
    ONCOLOGIST, 2023, 28 (05): : E309 - E312
  • [46] A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer
    Falchook, Gerald S.
    Reeves, James
    Gandhi, Sunil
    Spigel, David R.
    Arrowsmith, Edward
    George, Daniel J.
    Karlix, Janet
    Pouliot, Gayle
    Hattersley, Maureen M.
    Gangl, Eric T.
    James, Gareth D.
    Thompson, Jeff
    Russell, Deanna L.
    Patel, Bhavickumar
    Kumar, Rakesh
    Lim, Emerson
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (04)
  • [47] Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC)
    Garcia, Jorge A.
    Kataja, Vesa V.
    James, Nicholas David
    Jones, Robert Hugh
    Protheroe, Andrew
    Massard, Christophe
    Mattila, Leena
    Mustonen, Mika V. J.
    Aspegren, John
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
    Lin, Ting-Ting
    Chen, Ye-Hui
    Wu, Yu-Peng
    Chen, Shao-Zhan
    Li, Xiao-Dong
    Lin, Yun-Zhi
    Chen, Shao-Hao
    Zheng, Qing-Shui
    Wei, Yong
    Xu, Ning
    Xue, Xue-Yi
    JOURNAL OF CANCER, 2019, 10 (22): : 5608 - 5613
  • [49] Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
    Linch, M.
    Liu, G.
    Crabb, S. J.
    Beer, T. M.
    Heath, E.
    Gordon, M.
    de Bono, J. S.
    Pashova, H. I.
    Tudor, I. C.
    Custodio, J. M.
    Mann, G.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1183 - S1183
  • [50] Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands
    Wissing, Michel D.
    van Oort, Inge M.
    Gerritsen, Winald R.
    van den Eertwegh, Alfons J. M.
    Coenen, Jules L. L. M.
    Bergman, Andries M.
    Gelderblom, Hans
    CLINICAL GENITOURINARY CANCER, 2013, 11 (03) : 238 - +
12345